N. Baker

发表

Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa on hemoglobin response and symptoms in patients with heart failure and anemia

P. Ponikowski, K. Dickstein, A. Cohen-Solal, 2006 .

Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).

F. Locatelli, B. Canaud, A. Martín-Malo, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism.

H. Malluche, W. Goodman, J. Coburn, 2008, Clinical nephrology.

Safety and efficacy of darbepoetin alfa treatment in anemic patients with symptomatic heart failure: a pooled analysis of two randomized, double-blind, placebo-controlled trials

D. J. Veldhuisen, W. Abraham, M. Klapholz, 2006 .

Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.

P. Kerr, Y. Vanrenterghem, P. Bárány, 2002, Kidney international.

Pegfilgrastim successfully mobilizes megakaryocyte progenitors into the peripheral blood in subjects with solid tumours

R. Pettengell, P. Bacon, N. Baker, 2008, Bone Marrow Transplantation.

Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.

D. Cunningham, B. Karaszewska, M. Tejani, 2015 .

Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours

P. Woll, R. Pettengell, P. Bacon, 2009, Bone Marrow Transplantation.

A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial

R. Herrmann, J. Sierra, J. Szer, 2008, BMC Cancer.

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

R. Gelber, M. Piccart, S. Lakhani, 2021, The New England journal of medicine.

OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.

R. Gelber, A. Tutt, S. Lakhani, 2021 .

Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab

J. Baselga, J. Tabernero, F. Galimi, 2015, Targeted Oncology.

A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin’s lymphoma receiving chemotherapy

N. Schmitz, H. Johnsen, N. Russell, 2008, Haematologica.

Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.

P. Ponikowski, P. Poole‐Wilson, S. Anker, 2007, Journal of the American College of Cardiology.

Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.

J. Soria, L. Amler, E. Juhász, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.

P. Ponikowski, K. Dickstein, A. Cohen-Solal, 2008, European heart journal.

548 The effect of darbepoetin alfa treatment on clinical outcomes in anemic patients with symptomatic heart failure: a preplanned pooled analysis of two randomized, double‐blind, placebo‐controlled trials

D. J. Veldhuisen, W. Abraham, M. Klapholz, 2006 .

Oral cinacalcet HCI (AMG 073) for the treatment of hemodialysis patients with secondary hyperparathyroidism (HPT): Results of a European/Australian-Phase 3 study

Zani, F. Locatelli, P. Messa, 2003 .

Predictive value of Fc gamma receptor IIIa genotype in response to conatumumab in three phase II studies.

F. Galimi, Y. Hei, J. Graves, 2011, Journal of Clinical Oncology.

POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm).

M. Reni, G. Tortora, D. Hochhauser, 2016 .

741TiPRILOMET-1: AN INTERNATIONAL PHASE 3 MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF RILOTUMUMAB PLUS EPIRUBICIN, CISPLATIN AND CAPECITABINE (ECX) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED MET-POSITIVE GASTRIC OR GASTROESOPHAGEAL JUNCTION (G/GEJ) ADENOCARCINOMA.

D. Cunningham, N. Tebbutt, S. Al-Batran, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.